Tarlatamab for extensive-stage small-cell lung cancer with poor performance status
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with extensive-stage small-cell lung cancer that has spread or come back.
- You have already received at least one prior treatment for your cancer, including a platinum-based chemotherapy and a PD-L1 inhibitor.
- Your daily activity level is limited (ECOG performance status of 2), meaning you are up and about more than 50% of waking hours but may need rest.
- You have measurable disease (tumors that can be seen on scans).
- You do not have unstable brain metastases, severe bone marrow, liver, kidney, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
This study collects blood samples from people with small cell lung cancer or neuroendocrine tumors who are being treated with tarlatamab. The goal is to learn more about how the drug works in the body.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This study tests giving hospital-type care at home for people with extensive-stage small cell lung cancer who are receiving the drug Tarlatamab. It aims to see if patients can safely receive their treatment at home instead of in the hospital.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.